       Document 0594
 DOCN  M9630594
 TI    Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2
       recombinant Salmonella vaccines, induce long-lasting protection in
       rhesus macaques.
 DT    9603
 AU    Franchini G; Robert-Guroff M; Tartaglia J; Aggarwal A; Abimiku A; Benson
       J; Markham P; Limbach K; Hurteau G; Fullen J; et al; Laboratory of Tumor
       Cell Biology, National Cancer Institute,; National Institutes of Health,
       Bethesda, Maryland 20892, USA.
 SO    AIDS Res Hum Retroviruses. 1995 Aug;11(8):909-20. Unique Identifier :
       AIDSLINE GENBANK/J04498
 AB    Immunization schemes employing priming with vector-based vaccine
       candidates followed by subunit booster administrations have been
       explored and shown to have merit in the human immunodeficiency virus
       type 1 (HIV-1) and simian immunodeficiency virus systems. In this study,
       we have assessed the priming capacity of highly attenuated poxvirus
       vector (NYVAC and ALVAC)-based HIV-2 recombinants, as well as Salmonella
       typhimurium HIV-2 recombinants in rhesus macaques. ALVAC- and
       NYVAC-based vaccine candidates expressing the HIV-2 gag, pol, and env
       genes or NYVAC-based recombinants expressing either gp160 or gp120 were
       used to immunize rhesus macaques in combination protocols with
       alum-adjuvanted HIV-2 rgp160. Following intravenous challenge exposure
       with 100 infectious doses of the HIV-2SBL6669 parental virus genotype
       mixture, seven of eight animals were protected from infection. The seven
       protected animals were rechallenged 6 months postprimary challenge,
       without additional booster inoculations, with the same dose of the
       HIV-2SBL6669 parental virus. Five of the seven animals remained
       protected against HIV-2 infection at 6 months following the second
       challenge. In contrast, oral immunization with recombinant Salmonella
       expressing the HIV-2 gag and the gp120 portion of the envelope either
       alone or in combination with alum-adjuvanted rgp160 failed to confer
       protection. These results suggest that the NYVAC- and ALVAC-based
       recombinants may confer long-lasting protection and that these two
       highly attenuated poxvirus vaccine vectors may represent promising
       candidates for developing an acquired immunodeficiency syndrome vaccine.
 DE    Amino Acid Sequence  Animal  Base Sequence  Genetic Vectors  Human  HIV
       Infections/IMMUNOLOGY/*PREVENTION & CONTROL  HIV-2/GENETICS/*IMMUNOLOGY
       Macaca mulatta  Molecular Sequence Data  Poxviridae/GENETICS
       Salmonella/GENETICS  Support, Non-U.S. Gov't  Vaccines,
       Synthetic/GENETICS/IMMUNOLOGY/*THERAPEUTIC USE  Viral
       Proteins/GENETICS/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

